Assessing interleukin 23 in patients with systemic lupus erythematosus and lung disease
Official title: Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
Run by Sohag University · NCT06713187 · Data updated 2026-11-12
This study is testing the levels of a protein called interleukin 23 in people with systemic lupus erythematosus and lung disease to see how it might affect their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 2 sites (Sohag and 1 other locations) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | August 1, 2025 |
| Study ends | June 1, 2026 |
| Registry record updated | December 3, 2024 |
| Trial ID | NCT06713187 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with systemic lupus erythematosus, particularly those with interstitial lung disease.
✕Probably not a fit
Patients with chest conditions other than interstitial lung disease or those currently receiving biological blocking antibodies or immunosuppressive drugs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the levels of interleukin 23 in the serum of patients suffering from systemic lupus erythematosus (SLE) related interstitial lung disease. It involves a thorough clinical and rheumatological examination, along with the collection of SLEDAI scores and various laboratory tests, including erythrocyte sedimentation rate and complete blood count. The aim is to understand the role of interleukin 23 in this specific patient population and its potential implications for treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of systemic lupus erythematosus related lung disease.
How similar studies have gone: There is limited information on similar studies, making this approach relatively novel in the context of systemic lupus erythematosus and interstitial lung disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease. Exclusion Criteria: * patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.
Where it's running
-
Sohag university hospital
Sohag, Egypt Recruiting -
Sohag university
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Khadiga M Salem, resident doctor
- Email: khadiga_mahmoud_post@med.sohag.edu.eg
- Phone: 01069152448
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.